← Back to Screener
Precigen, Inc. Common Stock (PGEN)
Price$3.58
Value ScoreF
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-14.45%
Price vs S&P 500 (4W)-14.95%
VGM Score48.49
Market Capitalization$1.28B
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)83.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.86%
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)-22.51%
Gross Margin (TTM)80.12%
Net Profit Margin (TTM)-646.99%
EPS (TTM)$-0.66
10-Day Avg Trading Volume5.65M
EPS Excl Extra (TTM)$-0.66
Revenue Growth (5Y)-37.70%
EPS (Annual)$-0.80
ROI (Annual)-219.70%
Gross Margin (Annual)50.20%
Net Profit Margin (5Y Avg)-1576.92%
Cash / Share (Quarterly)$0.16
Revenue Growth QoQ (YoY)1633.93%
ROA (Last FY)-161.18%
Revenue Growth TTM (YoY)652.08%
EBITD / Share (TTM)$-0.28
ROE (5Y Avg)-306.45%
Operating Margin (TTM)-297.21%
Cash Flow / Share (Annual)$-0.25
P/B Ratio63.07x
P/B Ratio (Quarterly)67.69x
Net Income / Employee (Annual)$-1,566,500
EV / Revenue (TTM)43.12x
Net Interest Coverage (TTM)-383.42x
ROA (TTM)-144.14%
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)3.09x
Quick Ratio (Quarterly)3.93x
3-Month Avg Trading Volume4.43M
52-Week Price Return169.17%
Revenue / Employee (TTM)$197,500
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)131.80x
Asset Turnover (Annual)0.06x
52-Week High$5.47
Operating Margin (5Y Avg)-1421.40%
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)-23.33%
Tangible BV CAGR (5Y)58.01%
26-Week Price Return-6.53%
Quick Ratio (Annual)2.74x
13-Week Price Return6.23%
Total Debt / Equity (Annual)4.46x
Current Ratio (Quarterly)4.82x
Enterprise Value$1.36B
Revenue / Share Growth (5Y)-45.06%
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)-30.25%
Revenue / Employee (Annual)$60,500
Inventory Turnover (Annual)21.00x
Pretax Margin (Annual)-2588.18%
Cash / Share (Annual)$0.28
3-Month Return Std Dev88.35%
Gross Margin (5Y Avg)35.84%
Net Income / Employee (TTM)$-1,277,600
ROE (Last FY)-1198.61%
Net Interest Coverage (Annual)-38.59x
EPS Basic Excl Extra (Annual)$-0.80
Receivables Turnover (TTM)2.33x
Total Debt / Equity (Quarterly)4.62x
EPS Incl Extra (TTM)$-0.66
Receivables Turnover (Annual)4.00x
ROI (TTM)-147.09%
P/S Ratio (TTM)40.40x
Pretax Margin (5Y Avg)-1694.33%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.05
Forward P/E68.61x
Price vs S&P 500 (52W)144.81%
Year-to-Date Return-14.35%
5-Day Price Return-13.11%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-64.82%
Net Profit Margin (Annual)-2588.21%
Month-to-Date Return-17.51%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.34
Operating Margin (Annual)-1141.13%
LT Debt / Equity (Annual)4.46x
ROI (5Y Avg)-101.04%
LT Debt / Equity (Quarterly)4.62x
EPS Basic Excl Extra (TTM)$-0.66
P/TBV (Quarterly)78.85x
P/B Ratio (Annual)70.73x
Inventory Turnover (TTM)21.13x
Pretax Margin (TTM)-646.99%
Book Value / Share (Annual)$0.06
Price vs S&P 500 (13W)-2.02%
Beta1.16x
P/FCF (Annual)55.69x
Revenue / Share (TTM)$0.09
ROE (TTM)-642.46%
52-Week Low$1.30
vGradeF
gGradeB
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.02est. -0.03
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PGENPrecigen, Inc. Common Stock | F | B | B | $3.58 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Precigen Inc develops synthetic biology solutions and engineered gene programs for diverse applications across multiple industries. The company commercializes its technologies through exclusive strategic partnerships, generating revenue from technology access fees, royalties, and milestones. Operations are organized into two reportable segments: Biopharmaceuticals and Exemplar.